MEI Pharma Adds Cancer Drug Development Veteran Tom Reynolds to Board of Directors

   MEI Pharma Adds Cancer Drug Development Veteran Tom Reynolds to Board of
                                  Directors

PR Newswire

SAN DIEGO, Feb. 11, 2013

SAN DIEGO, Feb. 11, 2013 /PRNewswire/ --MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, announced today the appointment of Thomas C. Reynolds, M.D., Ph.D., to
its Board of Directors. A biotechnology industry veteran, Dr. Reynolds joins
the Board with more than 20 years of oncology drug development experience,
including direct oversight in the development and approval of the hematologic
cancer drug ADCETRIS^®.

(Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

"Dr. Reynolds' proven drug development expertise and valuable industry
perspective make him a welcome addition to our Board," said Daniel P. Gold,
Ph.D., President and Chief Executive Officer of MEI Pharma. "His appointment
is particularly timely as we prepare for the expansion of our clinical
development program for Pracinostat in the months ahead."

Dr. Reynolds served as Chief Medical Officer of Seattle Genetics from March
2007 until his retirement in February 2013. While at Seattle Genetics, he was
responsible for building and leading an integrated clinical development,
regulatory and medical affairs organization, highlighted by the development
and approval of ADCETRIS^®, an antibody-drug conjugate approved to treat
anaplastic large cell lymphoma and Hodgkin's lymphoma.

Previously, Dr. Reynolds served at ZymoGenetics (acquired by Bristol-Myers
Squibb in 2010), most recently as Vice President, Medical Affairs, where he
oversaw the clinical development and regulatory filing of RECOTHROM^®. Prior
to joining ZymoGenetics, he was Vice President, Clinical Affairs at Targeted
Genetics. Dr. Reynolds received his M.D. and Ph.D. in Biophysics from Stanford
University and a B.A. in Chemistry from Dartmouth College.

"I am delighted to join the Board of MEI Pharma at such an exciting time for
the company," said Dr. Reynolds. "I believe that MEI Pharma is poised to make
an immediate impact in the oncology arena with its lead drug candidate,
Pracinostat. I look forward to working closely with the rest of the Board and
management team to execute the optimal clinical development and marketing
approval strategy for Pracinostat and ultimately realize its significant
potential."

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's lead
drug candidate is Pracinostat, a potential best-in-class, oral histone
deacetylase (HDAC) inhibitor being developed for advanced hematologic
malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia
(AML). Results from a pilot Phase II clinical trial of Pracinostat in
combination with azacitidine in patients with advanced MDS were presented at
the American Society of Hematology Annual Meeting in December 2012 showing an
overall response rate (CR+CRi+PR) of 89% (eight out of nine). The Company
plans to initiate a randomized, placebo-controlled Phase II trial of
Pracinostat in combination with azacitidine in patients with MDS by June 2013.
In addition, MEI Pharma is developing two drug candidates derived from its
isoflavone-based technology platform, ME-143 and ME-344. For more information,
go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking
statements.

SOURCE MEI Pharma, Inc.

Website: http://www.meipharma.com
Contact: Pete De Spain, Sr. Director, Investor Relations & Corporate
Communications, +1-858-792-3729, pdespain@meipharma.com
 
Press spacebar to pause and continue. Press esc to stop.